- |||||||||| IMC-001 / Sorrento, Immuneoncia Therap, IMC001 / Immunofoco
Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers. (Hall A; Poster Bd #: 23) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3776;
This phase I study in advanced gastric cancer resulted in durable response with a favorable safety and efficacy profile especially for the recommended dose of 1M/kg, demonstrate a promising of EpCAM CAR-T therapy in advanced GC pts. Further expanding of this dose with larger patient population and longer follow-up shall bring the hope to this unmet medical need.
- |||||||||| IMC001 / Immunofoco
Peri Cruiser CAR-T: An innovative platform to reduce on-target off-tumor toxicity of CAR-T therapy. (On Demand | Hall A; Poster Bd # 381) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2308;
The Peri Cruiser CAR-T platform can significantly improve the safety of CAR-T cells without compromising their efficacy to eliminate tumor cells in primary site and metastasis. This technology opens another avenue to safely target a variety of other TAA by CAR-T even when there is the potential of on-target off-tumor toxicity in normal tissues for those antigens.
- |||||||||| IMC-001 / Sorrento, Immuneoncia Therap
EpCAM CAR T (IMC001) for the treatment of advanced GI cancers. (Available On Demand; Poster Bd # 355) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1163;
P1
IMC001 showed a favorable safety profile and reasonable anti-tumor activities at the low and middle dosage levels in patients with advanced EpCAM+ GI cancers, especially in gastric cancer. In addition, our trial has successfully provided a surgical treatment opportunity after CAR-T therapy downstaging of unresectable gastric cancers.
|
